Amicus Therapeutics, Inc. (NASDAQ:FOLD) has been given an average rating of “Buy” by the eight analysts that are currently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $19.32.
FOLD has been the topic of several analyst reports. ValuEngine upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. Cantor Fitzgerald reiterated a “buy” rating and issued a $20.00 target price on shares of Amicus Therapeutics in a research note on Tuesday, February 26th. BidaskClub upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 25th. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 4th. Finally, Citigroup upgraded shares of Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $12.59 target price on the stock in a research note on Wednesday, January 16th.
Get Amicus Therapeutics alerts:FOLD traded up $0.02 during midday trading on Wednesday, reaching $13.06. The company’s stock had a trading volume of 1,813,297 shares, compared to its average volume of 3,148,619. The stock has a market cap of $2.47 billion, a PE ratio of -9.82 and a beta of 1.77. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.03 and a current ratio of 9.12. Amicus Therapeutics has a 1 year low of $8.27 and a 1 year high of $17.62.
Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Thursday, February 28th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.13). The business had revenue of $32.64 million during the quarter, compared to analysts’ expectations of $30.81 million. Amicus Therapeutics had a negative return on equity of 52.03% and a negative net margin of 463.82%. Amicus Therapeutics’s revenue for the quarter was up 121.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.41) EPS. Equities research analysts predict that Amicus Therapeutics will post -1.1 EPS for the current year.
In other news, CEO John F. Crowley sold 103,500 shares of the company’s stock in a transaction that occurred on Tuesday, January 15th. The shares were sold at an average price of $11.71, for a total value of $1,211,985.00. Following the transaction, the chief executive officer now owns 771,581 shares in the company, valued at $9,035,213.51. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Bradley L. Campbell sold 36,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 22nd. The stock was sold at an average price of $11.81, for a total transaction of $425,160.00. Following the completion of the transaction, the chief operating officer now owns 275,360 shares in the company, valued at approximately $3,252,001.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 302,769 shares of company stock worth $3,668,771. Insiders own 2.90% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC lifted its position in Amicus Therapeutics by 9.0% during the fourth quarter. Geode Capital Management LLC now owns 2,183,679 shares of the biopharmaceutical company’s stock valued at $20,919,000 after purchasing an additional 180,938 shares during the period. Norges Bank bought a new position in Amicus Therapeutics during the fourth quarter valued at approximately $14,147,000. Dimensional Fund Advisors LP lifted its position in Amicus Therapeutics by 374.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,098,083 shares of the biopharmaceutical company’s stock valued at $10,518,000 after purchasing an additional 866,793 shares during the period. FMR LLC lifted its position in Amicus Therapeutics by 33.3% during the fourth quarter. FMR LLC now owns 17,943,523 shares of the biopharmaceutical company’s stock valued at $171,900,000 after purchasing an additional 4,479,743 shares during the period. Finally, Sofinnova Investments Inc. lifted its position in Amicus Therapeutics by 51.3% during the fourth quarter. Sofinnova Investments Inc. now owns 674,636 shares of the biopharmaceutical company’s stock valued at $6,462,000 after purchasing an additional 228,667 shares during the period.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.
Recommended Story: Diversification For Individual Investors
No comments:
Post a Comment